{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:13:11Z","timestamp":1789398791811,"version":"build-2803163510"},"reference-count":270,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004802","name":"California Breast Cancer Research Program","doi-asserted-by":"publisher","award":["W81XWH-21-1-0021"],"award-info":[{"award-number":["W81XWH-21-1-0021"]}],"id":[{"id":"10.13039\/100004802","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K22CA218472"],"award-info":[{"award-number":["K22CA218472"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R37CA282660"],"award-info":[{"award-number":["R37CA282660"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.phrs.2026.108372","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:43:42Z","timestamp":1786117422000},"page":"108372","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Clinical utilities of platelet-derived growth factor signaling in breast cancer"],"prefix":"10.1016","volume":"231","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1013-5242","authenticated-orcid":false,"given":"Jesse J.","family":"Reardon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6549-8140","authenticated-orcid":false,"given":"Alexis A.","family":"Mossing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5512-5669","authenticated-orcid":false,"given":"Rebecca L.","family":"Packard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajita","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4948-6171","authenticated-orcid":false,"given":"Gina M.","family":"Sizemore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib2","doi-asserted-by":"crossref","DOI":"10.3322\/caac.70043","article-title":"Cancer statistics, 2026","volume":"76","author":"Siegel","year":"2026","journal-title":"Ca-Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1038\/nrc2212","article-title":"Molecular heterogeneity of breast carcinomas and the cancer stem cell hypothesis","volume":"7","author":"Stingl","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib4","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nrc2193","article-title":"Modelling breast cancer: one size does not fit all","volume":"7","author":"Vargo-Gogola","year":"2007","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib5","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1172\/JCI107175","article-title":"Estrogen receptors in human breast cancer","volume":"52","author":"McGuire","year":"1973","journal-title":"J. Clin. Invest."},{"issue":"4785","key":"10.1016\/j.phrs.2026.108372_bib6","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1126\/science.3798106","article-title":"Human breast cancer: correlation of relapse and survival with amplification of the HER-2\/neu oncogene","volume":"235","author":"Slamon","year":"1987","journal-title":"Science"},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib7","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1158\/1078-0432.CCR-14-0432","article-title":"Comprehensive genomic analysis identifies novel subtypes and targets of triple-negative breast cancer","volume":"21","author":"Burstein","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib8","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest."},{"issue":"8","key":"10.1016\/j.phrs.2026.108372_bib9","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1200\/JCO.2008.18.1370","article-title":"Supervised risk predictor of breast cancer based on intrinsic subtypes","volume":"27","author":"Parker","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"6797","key":"10.1016\/j.phrs.2026.108372_bib10","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/35021093","article-title":"Molecular portraits of human breast tumours","volume":"406","author":"Perou","year":"2000","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.phrs.2026.108372_bib11","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"25","key":"10.1016\/j.phrs.2026.108372_bib12","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.1056\/NEJMoa021967","article-title":"A gene-expression signature as a predictor of survival in breast cancer","volume":"347","author":"Van De Vijver","year":"2002","journal-title":"New. Engl. J. Med."},{"issue":"1 3","key":"10.1016\/j.phrs.2026.108372_bib13","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/j.seminoncol.2004.01.004","article-title":"Therapeutic targeting in the estrogen receptor hormonal pathway","volume":"31","author":"Katzenellenbogen","year":"2004","journal-title":"Semin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib14","doi-asserted-by":"crossref","first-page":"e251","DOI":"10.1016\/j.clbc.2019.08.001","article-title":"A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast Cancer","volume":"20","author":"Mahtani","year":"2020","journal-title":"Clin. Breast Cancer"},{"issue":"20","key":"10.1016\/j.phrs.2026.108372_bib15","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.phrs.2026.108372_bib16","first-page":"1","article-title":"Novel Agents for Metastatic Triple-Negative Breast Cancer: Finding the Positive in the Negative","author":"Vidula","year":"2020","journal-title":"J. Natl. Compr. Canc Netw."},{"issue":"19","key":"10.1016\/j.phrs.2026.108372_bib17","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"S\u00f8rlie","year":"2001","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib18","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1309\/AJCPYO5FSV3UPEXS","article-title":"Breast cancer subtypes predispose the site of distant metastases","volume":"143","author":"Soni","year":"2015","journal-title":"Am. J. Clin. Pathol."},{"issue":"20","key":"10.1016\/j.phrs.2026.108372_bib19","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1200\/JCO.2009.25.9820","article-title":"Metastatic behavior of breast cancer subtypes","volume":"28","author":"Kennecke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.phrs.2026.108372_bib20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.semcancer.2015.08.009","article-title":"Clinical and molecular complexity of breast cancer metastases","volume":"35","author":"Kimbung","year":"2015","journal-title":"Semin. Cancer Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib21","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2944","article-title":"Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study","volume":"13","author":"Sihto","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib22","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1158\/0008-5472.CAN-07-5644","article-title":"Subtypes of breast cancer show preferential site of relapse","volume":"68","author":"Smid","year":"2008","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib23","first-page":"1","article-title":"Impact of molecular subtypes on metastatic breast cancer patients: a SEER population-based study","volume":"7","author":"Gong","year":"2017","journal-title":"Sci. Rep."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib24","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1007\/s00432-018-2697-2","article-title":"Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database","volume":"144","author":"Kim","year":"2018","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.phrs.2026.108372_bib25","doi-asserted-by":"crossref","first-page":"5763","DOI":"10.1073\/pnas.84.16.5763","article-title":"Synthesis and secretion of platelet-derived growth factor by human breast cancer cell lines","volume":"84","author":"Bronzert","year":"1987","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"12","key":"10.1016\/j.phrs.2026.108372_bib26","first-page":"2703","article-title":"Expression of platelet-derived growth factor B-chain and the platelet-derived growth factor receptor \u03b2 subunit in human breast tissue and breast carcinoma","volume":"55","author":"Coltrera","year":"1995","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib27","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/0960-0760(90)90428-N","article-title":"Growth factor expression in breast tissue","volume":"37","author":"Coombes","year":"1990","journal-title":"J. Steroid Biochem. Mol. Biol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib28","first-page":"351","article-title":"SIS\/PDGF-B expression in benign and malignant human breast lesions","volume":"4","author":"Ro","year":"1989","journal-title":"Oncogene"},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib29","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1002\/ijc.2910360218","article-title":"Production of PDGF-like growth factor by breast cancer cell lines","volume":"36","author":"Rozengurt","year":"1985","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib30","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/bs.acr.2022.01.003","article-title":"Diverse roles of tumor-stromal PDGFB-to-PDGFRbeta signaling in breast cancer growth and metastasis","volume":"154","author":"Shah","year":"2022","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108372_bib31","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.critrevonc.2018.05.004","article-title":"The clinical significance of platelet-derived growth factors (PDGFs) and their receptors (PDGFRs) in gastric cancer: A systematic review and meta-analysis","volume":"127","author":"Qian","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib32","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s10555-024-10194-7","article-title":"Functional and clinical roles of stromal PDGF receptors in tumor biology","volume":"43","author":"Strell","year":"2024","journal-title":"Cancer Metastas-.-. Rev."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib33","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3109\/03009734.2014.970304","article-title":"Platelet-derived growth factor in glioblastoma-driver or biomarker?","volume":"119","author":"Westermark","year":"2014","journal-title":"Ups. J. Med. Sci."},{"key":"10.1016\/j.phrs.2026.108372_bib34","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/4708076","article-title":"The role of PDGFs and PDGFRs in colorectal cancer","volume":"2017","author":"Manzat Saplacan","year":"2017","journal-title":"Mediat. Inflamm."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib35","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1101\/gad.1653708","article-title":"Role of platelet-derived growth factors in physiology and medicine","volume":"22","author":"Andrae","year":"2008","journal-title":"Genes. & Dev."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib36","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1038\/35074588","article-title":"PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor","volume":"3","author":"Bergsten","year":"2001","journal-title":"Nat. Cell. Biol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib37","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1038\/35010579","article-title":"PDGF-C is a new protease-activated ligand for the PDGF alpha-receptor","volume":"2","author":"Li","year":"2000","journal-title":"Nat. Cell. Biol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib38","first-page":"197","article-title":"The PDGF family: four gene products form five dimeric isoforms, Cytokine Growth Factor","volume":"15","author":"Fredriksson","year":"2004","journal-title":"Rev"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib39","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1242\/dev.115.4.1045","article-title":"Platelet-derived growth factor-A and its receptor are expressed in separate, but adjacent cell layers of the mouse embryo","volume":"115","author":"Orr-Urtreger","year":"1992","journal-title":"Development"},{"issue":"13","key":"10.1016\/j.phrs.2026.108372_bib40","doi-asserted-by":"crossref","first-page":"11281","DOI":"10.18632\/oncotarget.3596","article-title":"FoxM1 promotes breast tumorigenesis by activating PDGF-A and forming a positive feedback loop with the PDGF\/AKT signaling pathway","volume":"6","author":"Yu","year":"2015","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib41","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1158\/0008-5472.CAN-19-3560","article-title":"Gain of HIF1 Activity and Loss of miRNA let-7d Promote Breast Cancer Metastasis to the Brain via the PDGF\/PDGFR Axis","volume":"81","author":"Wyss","year":"2021","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib42","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1158\/0008-5472.CAN-19-3731","article-title":"Stromal Platelet-Derived Growth Factor Receptor-beta Signaling Promotes Breast Cancer Metastasis in the Brain","volume":"81","author":"Thies","year":"2021","journal-title":"Cancer Res."},{"issue":"38","key":"10.1016\/j.phrs.2026.108372_bib43","doi-asserted-by":"crossref","first-page":"4337","DOI":"10.1038\/sj.onc.1203785","article-title":"Human breast carcinoma desmoplasia is PDGF initiated","volume":"19","author":"Shao","year":"2000","journal-title":"Oncogene"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib44","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/bcr287","article-title":"The complexities of breast cancer desmoplasia","volume":"3","author":"Walker","year":"2001","journal-title":"Breast Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib45","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1073\/pnas.80.7.1919","article-title":"Cultured endothelial cells produce a platelet-derived growth factor-like protein","volume":"80","author":"DiCorleto","year":"1983","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib46","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3109\/08977199209046408","article-title":"Platelet-derived growth factor is angiogenic in vivo","volume":"7","author":"Risau","year":"1992","journal-title":"Growth Factors"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms3129","article-title":"Tumour PDGF-BB expression levels determine dual effects of anti-PDGF drugs on vascular remodelling and metastasis","volume":"4","author":"Hosaka","year":"2013","journal-title":"Nat. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib48","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1172\/JCI24652","article-title":"Autocrine PDGFR signaling promotes mammary cancer metastasis","volume":"116","author":"Jechlinger","year":"2006","journal-title":"J. Clin. Investig."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib49","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.molonc.2013.12.009","article-title":"LIM-homeobox gene 2 promotes tumor growth and metastasis by inducing autocrine and paracrine PDGF-B signaling","volume":"8","author":"Kuzmanov","year":"2014","journal-title":"Mol. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib50","first-page":"1","article-title":"Metformin inhibits metastatic breast cancer progression and improves chemosensitivity by inducing vessel normalization via PDGF-B downregulation","volume":"38","author":"Wang","year":"2019","journal-title":"J. Exp. & Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-019-1114-3","article-title":"CXCL17-derived CD11b+ Gr-1+ myeloid-derived suppressor cells contribute to lung metastasis of breast cancer through platelet-derived growth factor-BB","volume":"21","author":"Hsu","year":"2019","journal-title":"Breast Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib52","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.bbrc.2010.06.132","article-title":"Breast cancer cells attract the migration of adipose tissue-derived stem cells via the PDGF-BB\/PDGFR-\u03b2 signaling pathway","volume":"398","author":"Gehmert","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib53","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1016\/j.biomaterials.2007.11.026","article-title":"Dermal matrix as a carrier for in vivo delivery of human adipose-derived stem cells","volume":"29","author":"Altman","year":"2008","journal-title":"Biomaterials"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib54","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ccr.2004.08.034","article-title":"PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis","volume":"6","author":"Cao","year":"2004","journal-title":"Cancer Cell."},{"issue":"4958","key":"10.1016\/j.phrs.2026.108372_bib55","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1126\/science.2343305","article-title":"Localization of PDGF-B protein in macrophages in all phases of atherogenesis","volume":"248","author":"Ross","year":"1990","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib56","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S0002-9440(10)62061-5","article-title":"The absence of platelet-derived growth factor-B in circulating cells promotes immune and inflammatory responses in atherosclerosis-prone ApoE-\/- mice","volume":"167","author":"Tang","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"23","key":"10.1016\/j.phrs.2026.108372_bib57","doi-asserted-by":"crossref","first-page":"5722","DOI":"10.1158\/1078-0432.CCR-10-1693","article-title":"Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses","volume":"16","author":"Kong","year":"2010","journal-title":"Clin. Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s13402-018-0371-y","article-title":"Cancer-associated fibroblasts affect breast cancer cell gene expression, invasion and angiogenesis","volume":"41","author":"Eiro","year":"2018","journal-title":"Cell Oncol (Dordr)"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib59","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1152\/physrev.1999.79.4.1283","article-title":"Mechanism of Action and In Vivo Role of Platelet-Derived Growth Factor","volume":"79","author":"Heldin","year":"1999","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.phrs.2026.108372_bib60","doi-asserted-by":"crossref","unstructured":"A. Bottrell, Y.H. Meng, A.J. Najy, N. Hurst, Jr, S. Kim, C.J. Kim, E.S. Kim, A. Moon, E.J. Kim, S.Y. Park, H.C. Kim, An oncogenic activity of PDGF-C and its splice variant in human breast cancer, Growth Factors 37 (3\u20134) (2019) 131\u2013145.","DOI":"10.1080\/08977194.2019.1662415"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib61","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1042\/BJ20111020","article-title":"Platelet-derived growth factor-C (PDGF-C) activation by serine proteases: implications for breast cancer progression","volume":"441","author":"Hurst","year":"2012","journal-title":"Biochem. J."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib62","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/nm.4494","article-title":"Microenvironmental control of breast cancer subtype elicited through paracrine platelet-derived growth factor-CC signaling","volume":"24","author":"Roswall","year":"2018","journal-title":"Nat. Med."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib63","doi-asserted-by":"crossref","first-page":"6225","DOI":"10.1074\/jbc.M113.508994","article-title":"Platelet-derived growth factor-C (PDGF-C) induces anti-apoptotic effects on macrophages through Akt and Bad phosphorylation","volume":"289","author":"Son","year":"2014","journal-title":"J. Biol. Chem."},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib64","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1158\/1078-0432.CCR-10-2456","article-title":"PDGF-D improves drug delivery and efficacy via vascular normalization, but promotes lymphatic metastasis by activating CXCR4 in breast cancer","volume":"17","author":"Liu","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib65","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.clbc.2021.06.002","article-title":"Downregulation of PDGF-D Inhibits Proliferation and Invasion in Breast Cancer MDA-MB-231 Cells","volume":"22","author":"Lu","year":"2022","journal-title":"Clin. Breast Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib66","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ijc.26493","article-title":"Epithelial-mesenchymal transition in breast cancer lines is mediated through PDGF-D released by tissue-resident stem cells","volume":"131","author":"Devarajan","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib67","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.neo.2017.04.004","article-title":"Stromal PDGFR-alpha Activation Enhances Matrix Stiffness, Impedes Mammary Ductal Development, and Accelerates Tumor Growth","volume":"19","author":"Hammer","year":"2017","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib68","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1038\/s43018-023-00525-y","article-title":"Age-associated microenvironmental changes highlight the role of PDGF-C in ER+ breast cancer metastatic relapse","volume":"4","author":"Turrell","year":"2023","journal-title":"Nat. Cancer"},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib69","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1038\/s41588-021-00911-1","article-title":"A single-cell and spatially resolved atlas of human breast cancers","volume":"53","author":"Wu","year":"2021","journal-title":"Nat. Genet."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib70","doi-asserted-by":"crossref","DOI":"10.1186\/bcr1304","article-title":"Overexpression of platelet-derived growth factor receptor \u03b1 in breast cancer is associated with tumour progression","volume":"7","author":"Carvalho","year":"2005","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib71","doi-asserted-by":"crossref","first-page":"334","DOI":"10.2353\/ajpath.2009.081030","article-title":"Prognostic significance of stromal platelet-derived growth factor \u03b2-receptor expression in human breast cancer","volume":"175","author":"Paulsson","year":"2009","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib72","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10549-015-3291-9","article-title":"Differential expression of cancer-associated fibroblast-related proteins according to molecular subtype and stromal histology in breast cancer","volume":"149","author":"Park","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib73","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-018-4664-7","article-title":"The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence","volume":"169","author":"Jansson","year":"2018","journal-title":"Breast Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib74","first-page":"773","article-title":"Localization of platelet-derived growth factor beta receptor expression in the periepithelial stroma of human breast carcinoma","volume":"2","author":"Bhardwaj","year":"1996","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib75","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-018-4500-9","article-title":"The PDGFR\u03b2\/ERK1\/2 pathway regulates CDCP1 expression in triple-negative breast cancer","volume":"18","author":"Forte","year":"2018","journal-title":"BMC Cancer"},{"issue":"18","key":"10.1016\/j.phrs.2026.108372_bib76","doi-asserted-by":"crossref","first-page":"5178","DOI":"10.7150\/thno.27798","article-title":"Targeted imaging and inhibition of triple-negative breast cancer metastases by a PDGFR\u03b2 aptamer","volume":"8","author":"Camorani","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.phrs.2026.108372_bib77","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1186\/s12967-015-0587-9","article-title":"Expression of cancer-associated fibroblast related proteins in metastatic breast cancer: an immunohistochemical analysis","volume":"13","author":"Kim","year":"2015","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.phrs.2026.108372_bib78","doi-asserted-by":"crossref","first-page":"17948","DOI":"10.1038\/srep17948","article-title":"PDGFR\u03b1 plays a crucial role in connective tissue remodeling","volume":"5","author":"Horikawa","year":"2015","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib79","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"cell"},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib80","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"6516","key":"10.1016\/j.phrs.2026.108372_bib81","doi-asserted-by":"crossref","DOI":"10.1126\/science.aaz0868","article-title":"Physical traits of cancer","volume":"370","author":"Nia","year":"2020","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib82","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/nrc1456","article-title":"High interstitial fluid pressure - an obstacle in cancer therapy","volume":"4","author":"Heldin","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib83","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1172\/JCI125890","article-title":"Stromal integrin alpha11 regulates PDGFR-beta signaling and promotes breast cancer progression","volume":"129","author":"Primac","year":"2019","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.phrs.2026.108372_bib84","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-11-480","article-title":"Mammary tumors that become independent of the type I insulin-like growth factor receptor express elevated levels of platelet-derived growth factor receptors","volume":"11","author":"Campbell","year":"2011","journal-title":"BMC Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib85","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.ccr.2013.08.005","article-title":"Protein kinase C \u03b1 is a central signaling node and therapeutic target for breast cancer stem cells","volume":"24","author":"Tam","year":"2013","journal-title":"Cancer Cell."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib86","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1158\/0008-5472.CAN-13-3029","article-title":"PDGFR\u03b1 and \u03b2 play critical roles in mediating Foxq1-driven breast cancer stemness and chemoresistance","volume":"75","author":"Meng","year":"2015","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib87","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1016\/j.ajpath.2013.02.018","article-title":"Prognostic significance in breast cancer of a gene signature capturing stromal PDGF signaling","volume":"182","author":"Frings","year":"2013","journal-title":"Am. J. Pathol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib88","first-page":"45","article-title":"Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial, Breast Cancer Res","volume":"187","author":"Strell","year":"2021","journal-title":"Treat"},{"key":"10.1016\/j.phrs.2026.108372_bib89","doi-asserted-by":"crossref","unstructured":"M. Brama, L. Gnessi, S. Basciani, N. Cerulli, L. Politi, G. Spera, S. Mariani, S. Cherubini, Scotto d\u2019Abusco, A. Scandurra, R. Migliaccio, S. Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism, Mol. Cell. Endocrinol. 264 (1\u20132) (2007) 102\u2013108.","DOI":"10.1016\/j.mce.2006.10.013"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib90","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1158\/1078-0432.CCR-10-1603","article-title":"Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis","volume":"17","author":"Gril","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108372_bib91","doi-asserted-by":"crossref","first-page":"173868","DOI":"10.1016\/j.ejphar.2021.173868","article-title":"Inhibition of platelet-derived growth factor C and their receptors additionally increases doxorubicin effects in triple-negative breast cancer cells","volume":"895","author":"Kim","year":"2021","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib92","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.7150\/jca.13141","article-title":"Cancer Hallmarks, Biomarkers and Breast Cancer Molecular Subtypes","volume":"7","author":"Dai","year":"2016","journal-title":"J. Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib93","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.3389\/fonc.2020.01230","article-title":"SHP-2-Mediated Upregulation of ZEB1 Is Important for PDGF-B-Induced Cell Proliferation and Metastatic Phenotype in Triple Negative Breast Cancer","volume":"10","author":"Zhang","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib94","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00665774","article-title":"Positive immunostaining for platelet derived growth factor (PDGF) is an adverse prognostic factor in patients with advanced breast cancer","volume":"32","author":"Seymour","year":"1994","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.phrs.2026.108372_bib95","doi-asserted-by":"crossref","first-page":"155487","DOI":"10.1016\/j.cyto.2021.155487","article-title":"Prognostic effects of cytokine levels on patients treated with taxane and zoledronic acid for metastatic breast cancer in bone (BEAT-ZO) (KCSG BR 10-13)","volume":"142","author":"Kim","year":"2021","journal-title":"Cytokine"},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib96","doi-asserted-by":"crossref","first-page":"499","DOI":"10.4143\/crt.2015.089","article-title":"Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer","volume":"48","author":"Yoo","year":"2016","journal-title":"Cancer Res. Treat."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3892\/ol.2021.12555","article-title":"Inhibition of platelet\u2011derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor \u03b1 positive breast cancer","volume":"21","author":"Kim","year":"2021","journal-title":"Oncol. Lett."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib98","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10549-024-07492-7","article-title":"The cytokine profile correlates with less tumor-infiltrating lymphocytes in luminal A breast cancer","volume":"209","author":"Ishikawa","year":"2025","journal-title":"Breast Cancer Res. Treat."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib99","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.bbrc.2018.06.106","article-title":"PDGF family function and prognostic value in tumor biology","volume":"503","author":"Bartoschek","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib100","doi-asserted-by":"crossref","first-page":"20306","DOI":"10.3390\/ijms151120306","article-title":"Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer","volume":"15","author":"Luo","year":"2014","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.phrs.2026.108372_bib101","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research N. Comprehensive molecular profiling of lung adenocarcinoma 7511 511 Nature2014, 543550.","DOI":"10.1038\/nature13385"},{"issue":"7403","key":"10.1016\/j.phrs.2026.108372_bib102","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature10983","article-title":"The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups","volume":"486","author":"Curtis","year":"2012","journal-title":"Nature"},{"issue":"7748","key":"10.1016\/j.phrs.2026.108372_bib103","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41586-019-1007-8","article-title":"Dynamics of breast-cancer relapse reveal late-recurring ER-positive genomic subgroups","volume":"567","author":"Rueda","year":"2019","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib104","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.neo.2017.03.002","article-title":"Characterization and Targeting of Platelet-Derived Growth Factor Receptor alpha (PDGFRA) in Inflammatory Breast Cancer (IBC)","volume":"19","author":"Joglekar-Javadekar","year":"2017","journal-title":"Neoplasia"},{"issue":"12","key":"10.1016\/j.phrs.2026.108372_bib105","doi-asserted-by":"crossref","first-page":"3469","DOI":"10.1158\/1078-0432.CCR-20-4300","article-title":"High PDGFRb Expression Predicts Resistance to Radiotherapy in DCIS within the SweDCIS Randomized Trial","volume":"27","author":"Strell","year":"2021","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib106","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1093\/annonc\/mds240","article-title":"Enhanced expression of the PDGFR\/Abl signaling pathway in aromatase inhibitor-resistant breast cancer","volume":"24","author":"Weigel","year":"2013","journal-title":"Ann. Oncol."},{"issue":"6036","key":"10.1016\/j.phrs.2026.108372_bib107","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/317438a0","article-title":"Antibodies against platelet-derived growth factor inhibit acute transformation by simian sarcoma virus","volume":"317","author":"Johnsson","year":"1985","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib108","doi-asserted-by":"crossref","first-page":"852","DOI":"10.3171\/jns.1996.84.5.0852","article-title":"Autocrine growth stimulation of human meningioma cells by platelet-derived growth factor","volume":"84","author":"Todo","year":"1996","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib109","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neulet.2008.12.044","article-title":"Platelet-derived growth factor BB promotes the migration of bone marrow-derived mesenchymal stem cells towards C6 glioma and up-regulates the expression of intracellular adhesion molecule-1","volume":"451","author":"Cheng","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.phrs.2026.108372_bib110","doi-asserted-by":"crossref","unstructured":"J. Yang, X.Liu, S.B. Nyland, R. Zhang, L.K. Ryland, K. Broeg, K.T. Baab, N.R. Jarbadan, R. Irby, T.P.Jr Loughran, Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway, Blood (2010).","DOI":"10.1182\/blood-2009-06-223719"},{"key":"10.1016\/j.phrs.2026.108372_bib111","doi-asserted-by":"crossref","unstructured":"N.Hata, N. Shinojima, J. Gumin, R. Yong, F. Marini, M. Andreeff, F.F. Lang, Platelet-derived growth factor BB mediates the tropism of human mesenchymal stem cells for malignant gliomas, Neurosurgery 66 (1) (2010) 144\u2013156.","DOI":"10.1227\/01.NEU.0000363149.58885.2E"},{"issue":"8","key":"10.1016\/j.phrs.2026.108372_bib112","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.1210\/endo.140.8.6921","article-title":"Transforming growth factor-beta1-induced proliferation of the prostate cancer cell line, TSU-Pr1: the role of platelet-derived growth factor","volume":"140","author":"Sintich","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.phrs.2026.108372_bib113","first-page":"917","article-title":"Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer","volume":"62","author":"Yi","year":"2002","journal-title":"Cancer Res"},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib114","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.yexcr.2005.07.029","article-title":"Cytokines secreted by bone-metastatic breast cancer cells alter the expression pattern of f-actin and reduce focal adhesion plaques in osteoblasts through PI3K","volume":"310","author":"Mercer","year":"2005","journal-title":"Exp. Cell. Res."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib115","first-page":"1","article-title":"Radiation-induced senescence in securin-deficient cancer cells promotes cell invasion involving the IL-6\/STAT3 and PDGF-BB\/PDGFR pathways","volume":"3","author":"Yu","year":"2013","journal-title":"Sci. Rep."},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib116","first-page":"871","article-title":"Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1","volume":"45","author":"Banerjee","year":"2006","journal-title":"Molecular Carcinogenesis Published cooperation University Texas MD Anderson Cancer Center"},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib117","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1021\/bi5015425","article-title":"Characterization of binding mode of action of a blocking anti-platelet-derived growth factor (PDGF)-B monoclonal antibody, MOR8457, reveals conformational flexibility and avidity needed for PDGF-BB to bind PDGF receptor-\u03b2","volume":"54","author":"Kuai","year":"2015","journal-title":"Biochemistry"},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib118","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.2353\/ajpath.2006.050588","article-title":"Inhibition of platelet-derived growth factor B signaling enhances the efficacy of anti-vascular endothelial growth factor therapy in multiple models of ocular neovascularization","volume":"168","author":"Jo","year":"2006","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib119","doi-asserted-by":"crossref","first-page":"543","DOI":"10.3233\/CH-189319","article-title":"PDGF regulated migration of mesenchymal stem cells towards malignancy acts via the PI3K signaling pathway","volume":"70","author":"Salha","year":"2018","journal-title":"Clin. Hemorheol. Microcirc."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib120","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.bbrc.2007.04.075","article-title":"An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody","volume":"357","author":"Shen","year":"2007","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib121","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1593\/neo.09278","article-title":"Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody","volume":"11","author":"Shen","year":"2009","journal-title":"Neoplasia"},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib122","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1200\/JCO.2005.01.032","article-title":"Blockade of platelet-derived growth factor receptor-beta by CDP860, a humanized, PEGylated di-Fab', leads to fluid accumulation and is associated with increased tumor vascularized volume","volume":"23","author":"Jayson","year":"2005","journal-title":"J. Clin. Oncol."},{"issue":"10043","key":"10.1016\/j.phrs.2026.108372_bib123","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/S0140-6736(16)30587-6","article-title":"Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial","volume":"388","author":"Tap","year":"2016","journal-title":"Lancet"},{"issue":"13","key":"10.1016\/j.phrs.2026.108372_bib124","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1001\/jama.2020.1707","article-title":"Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial","volume":"323","author":"Tap","year":"2020","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/cpt.2081","article-title":"Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab","volume":"110","author":"Papachristos","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib126","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/cam4.3658","article-title":"Phase 1 trial of olaratumab monotherapy and in combination with chemotherapy in pediatric patients with relapsed\/refractory solid and central nervous system tumors","volume":"10","author":"Mascarenhas","year":"2021","journal-title":"Cancer Med."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib127","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1186\/s12885-018-5198-4","article-title":"Randomized phase II study of the PDGFRalpha antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer","volume":"18","author":"McGuire","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib128","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ejca.2018.10.005","article-title":"Randomised phase II study of second-line olaratumab with mitoxantrone\/prednisone versus mitoxantrone\/prednisone alone in metastatic castration-resistant prostate cancer","volume":"107","author":"Hakenberg","year":"2019","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib129","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.lungcan.2017.07.009","article-title":"Phase II study of olaratumab with paclitaxel\/carboplatin (P\/C) or P\/C alone in previously untreated advanced NSCLC","volume":"111","author":"Gerber","year":"2017","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib130","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/annonc\/mdw659","article-title":"A phase II study of a human anti-PDGFRalpha monoclonal antibody (olaratumab, IMC-3G3) in previously treated patients with metastatic gastrointestinal stromal tumors","volume":"28","author":"Wagner","year":"2017","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib131","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2018-000479","article-title":"Olaratumab administered in two cases of phyllodes tumour of the breast: end of the beginning?","volume":"4","author":"Kyriazoglou","year":"2019","journal-title":"ESMO Open."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib132","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2223750","article-title":"A PDGFRB- and CD40-targeting bispecific AffiMab induces stroma-targeted immune cell activation","volume":"15","author":"Mega","year":"2023","journal-title":"MAbs"},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib133","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.7150\/thno.11711","article-title":"Superior performance of aptamer in tumor penetration over antibody: implication of aptamer-based theranostics in solid tumors","volume":"5","author":"Xiang","year":"2015","journal-title":"Theranostics"},{"issue":"45","key":"10.1016\/j.phrs.2026.108372_bib134","doi-asserted-by":"crossref","first-page":"14413","DOI":"10.1021\/bi961544+","article-title":"Inhibitory DNA ligands to platelet-derived growth factor B-chain","volume":"35","author":"Green","year":"1996","journal-title":"Biochemistry"},{"issue":"19","key":"10.1016\/j.phrs.2026.108372_bib135","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res."},{"issue":"15","key":"10.1016\/j.phrs.2026.108372_bib136","doi-asserted-by":"crossref","first-page":"7358","DOI":"10.1158\/0008-5472.CAN-07-0293","article-title":"Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102","volume":"67","author":"Sennino","year":"2007","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib137","doi-asserted-by":"crossref","first-page":"2920","DOI":"10.1016\/j.ajpath.2011.02.019","article-title":"Increased vascular delivery and efficacy of chemotherapy after inhibition of platelet-derived growth factor-B","volume":"178","author":"Falcon","year":"2011","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib138","doi-asserted-by":"crossref","first-page":"176","DOI":"10.4161\/cbt.9.3.10635","article-title":"Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models","volume":"9","author":"Lu","year":"2010","journal-title":"Cancer Biol. Ther."},{"issue":"14","key":"10.1016\/j.phrs.2026.108372_bib139","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.7150\/thno.18974","article-title":"Inhibition of bone marrow-derived mesenchymal stem cells homing towards triple-negative breast cancer microenvironment using an anti-PDGFR\u03b2 aptamer","volume":"7","author":"Camorani","year":"2017","journal-title":"Theranostics"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-020-01694-9","article-title":"Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer","volume":"39","author":"Camorani","year":"2020","journal-title":"J. Exp. & Clin. Cancer Res."},{"key":"10.1016\/j.phrs.2026.108372_bib141","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.mam.2017.11.007","article-title":"The PDGF\/PDGFR pathway as a drug target","volume":"62","author":"Papadopoulos","year":"2018","journal-title":"Mol. Asp. Med."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib142","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrd839","article-title":"Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug","volume":"1","author":"Capdeville","year":"2002","journal-title":"Nat. Rev. Drug. Discov."},{"issue":"5486","key":"10.1016\/j.phrs.2026.108372_bib143","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1126\/science.289.5486.1938","article-title":"Structural mechanism for STI-571 inhibition of abelson tyrosine kinase","volume":"289","author":"Schindler","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.phrs.2026.108372_bib144","unstructured":"Drug approval package: Gleevec (imatinib) NDA #021335s003. [Internet]. 2003 [cited December 2025]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2003\/21-335s003_21-588s001_Gleevec.cfm."},{"key":"10.1016\/j.phrs.2026.108372_bib145","unstructured":"A.E. Roussidis, T.N. Mitropoulou, A.D. Theocharis, C. Kiamouris, S. Papadopoulos, D. Kletsas, et al., STI571 as a potent inhibitor of growth and invasiveness of human epithelial breast cancer cells, Anticancer. Res. 24 (3A) (2004) 1445\u20131448."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib146","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2008.07.040","article-title":"Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR \u03b2 signalling","volume":"273","author":"Weigel","year":"2009","journal-title":"Cancer Lett."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib147","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1111\/febs.12163","article-title":"Imatinib as a key inhibitor of the platelet-derived growth factor receptor mediated expression of cell surface heparan sulfate proteoglycans and functional properties of breast cancer cells","volume":"280","author":"Malavaki","year":"2013","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib148","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1582-4934.2010.01236.x","article-title":"Proteoglycans in cancer biology, tumour microenvironment and angiogenesis","volume":"15","author":"Iozzo","year":"2011","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.phrs.2026.108372_bib149","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/scdb.2000.0241","article-title":"Heparan sulfate proteoglycans in invasion and metastasis","author":"Sanderson","year":"2001","journal-title":"Semin. Cell. & Dev. Biol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib150","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1158\/1078-0432.306.11.1","article-title":"Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice","volume":"11","author":"Lev","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib151","first-page":"2929","article-title":"Inhibition of platelet-derived growth factor receptors reduces interstitial hypertension and increases transcapillary transport in tumors","volume":"61","author":"Pietras","year":"2001","journal-title":"Cancer Res."},{"issue":"19","key":"10.1016\/j.phrs.2026.108372_bib152","first-page":"5476","article-title":"Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy","volume":"62","author":"Pietras","year":"2002","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib153","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s10549-004-3974-0","article-title":"A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer","volume":"90","author":"Modi","year":"2005","journal-title":"Breast Cancer Res. Treat."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib154","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdn352","article-title":"Imatinib mesylate (Gleevec\u00ae) in advanced breast cancer-expressing C-Kit or PDGFR-\u03b2: clinical activity and biological correlations","volume":"19","author":"Cristofanilli","year":"2008","journal-title":"Ann. Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib155","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2003-12-4266","article-title":"Vuk-Pavlovic S. Imatinib mesylate inhibits T-cell proliferation in vitro and delayed-type hypersensitivity in vivo","volume":"104","author":"Dietz","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib156","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1182\/blood-2003-03-0975","article-title":"Imatinib mesylate affects the development and function of dendritic cells generated from CD34+ peripheral blood progenitor cells","volume":"103","author":"Appel","year":"2004","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib157","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1038\/sj.leu.2403933","article-title":"Imatinib mesylate suppresses cytokine synthesis by activated CD4 T cells of patients with chronic myelogenous leukemia","volume":"19","author":"Gao","year":"2005","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib158","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3816\/CBC.2009.n.040","article-title":"Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer","volume":"9","author":"Yardley","year":"2009","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib159","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s10549-011-1413-6","article-title":"Docetaxel metabolism is not altered by imatinib: findings from an early phase study in metastatic breast cancer","volume":"127","author":"Connolly","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib160","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3816\/CBC.2008.n.062","article-title":"A phase II study of imatinib mesylate and capecitabine in metastatic breast cancer: Southwest Oncology Group Study 0338","volume":"8","author":"Chew","year":"2008","journal-title":"Clin. Breast Cancer"},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib161","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s10637-018-0672-z","article-title":"A phase II study of imatinib mesylate and letrozole in patients with hormone receptor-positive metastatic breast cancer expressing c-kit or PDGFR-\u03b2","volume":"36","author":"Yam","year":"2018","journal-title":"Investig. New. Drugs"},{"issue":"15","key":"10.1016\/j.phrs.2026.108372_bib162","doi-asserted-by":"crossref","first-page":"4632","DOI":"10.1021\/jm800566m","article-title":"Discovery of 5-[[4-[(2, 3-dimethyl-2H-indazol-6-yl) methylamino]-2-pyrimidinyl] amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor","volume":"51","author":"Harris","year":"2008","journal-title":"J. Med. Chem."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib163","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s11912-007-0007-2","article-title":"Pazopanib: a novel multitargeted tyrosine kinase inhibitor","volume":"9","author":"Sonpavde","year":"2007","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.phrs.2026.108372_bib164","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib165","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.2217\/fon.09.112","article-title":"Pazopanib: an antiangiogenic drug in perspective","volume":"5","author":"Castaneda","year":"2009","journal-title":"Future Oncol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108372_bib166","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1517\/14656560903436493","article-title":"Pazopanib: therapeutic developments","volume":"10","author":"Limvorasak","year":"2009","journal-title":"Expert. Opin. Pharmacother."},{"issue":"12","key":"10.1016\/j.phrs.2026.108372_bib167","first-page":"1324","article-title":"Pazopanib, a VEGF receptor tyrosine kinase inhibitor for cancer therapy","volume":"9","author":"Sloan","year":"2008","journal-title":"Current opinion investigational drugs (London England 2000)"},{"issue":"40","key":"10.1016\/j.phrs.2026.108372_bib168","doi-asserted-by":"crossref","first-page":"42396","DOI":"10.18632\/oncotarget.6377","article-title":"Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer","volume":"6","author":"Di Desidero","year":"2015","journal-title":"Oncotarget"},{"issue":"12","key":"10.1016\/j.phrs.2026.108372_bib169","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","article-title":"Phase I trial of pazopanib in patients with advanced cancer","volume":"15","author":"Hurwitz","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"10.1016\/j.phrs.2026.108372_bib170","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1634\/theoncologist.2010-0095","article-title":"Phase I study of pazopanib in combination with weekly paclitaxel in patients with advanced solid tumors","volume":"15","author":"Tan","year":"2010","journal-title":"oncologist"},{"key":"10.1016\/j.phrs.2026.108372_bib171","article-title":"Abstract A6: Pazopanib combination with paclitaxel and carboplatin in patients with advanced solid tumors and gynecological cancers: Results of two phase I studies","author":"Burris","year":"2009","journal-title":"AACR"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib172","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s10549-012-2399-4","article-title":"A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer","volume":"137","author":"Johnston","year":"2013","journal-title":"Breast Cancer Res. Treat."},{"issue":"15_","key":"10.1016\/j.phrs.2026.108372_bib173","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1200\/jco.2008.26.15_suppl.1016","article-title":"Randomized study of pazopanib+ lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer","volume":"26","author":"Slamon","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib174","first-page":"471","article-title":"SU11248 inhibits KIT and platelet-derived growth factor receptor \u03b2 in preclinical models of human small cell lung cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol. Cancer Ther."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib175","first-page":"327","article-title":"vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin. Cancer Res."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib176","first-page":"3597","article-title":"SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo","volume":"101","author":"O\u2019Farrell","year":"2003","journal-title":"Blood J. Am. Soc. Hematol."},{"issue":"8","key":"10.1016\/j.phrs.2026.108372_bib177","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1023\/B:CLIN.0000006873.65590.68","article-title":"SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model","volume":"20","author":"Murray","year":"2003","journal-title":"Clin. & Exp. Metastas-.-."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib178","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ncponc0905","article-title":"Mechanisms of disease: angiogenesis and the management of breast cancer","volume":"4","author":"Banerjee","year":"2007","journal-title":"Nat. Clin. Pract. Oncol."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib179","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1349-7006.2005.00009.x","article-title":"Correlation of KIT and EGFR overexpression with invasive ductal breast carcinoma of the solid-tubular subtype, nuclear grade 3, and mesenchymal or myoepithelial differentiation","volume":"96","author":"Tsuda","year":"2005","journal-title":"Cancer Sci."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib180","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.clbc.2011.03.005","article-title":"Sunitinib plus paclitaxel versus bevacizumab plus paclitaxel for first-line treatment of patients with advanced breast cancer: a phase III, randomized, open-label trial","volume":"11","author":"Robert","year":"2011","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib181","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/2045-824X-6-12","article-title":"Sunitinib significantly suppresses the proliferation, migration, apoptosis resistance, tumor angiogenesis and growth of triple-negative breast cancers but increases breast cancer stem cells","volume":"6","author":"Chinchar","year":"2014","journal-title":"Vasc. Cell."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib182","first-page":"4899","article-title":"Sunitinib Inhibits Breast Cancer Cell Proliferation by Inducing Apoptosis, Cell-cycle Arrest and DNA Repair While Inhibiting NF-kappaB Signaling Pathways","volume":"37","author":"Korashy","year":"2017","journal-title":"Anticancer. Res."},{"issue":"15_","key":"10.1016\/j.phrs.2026.108372_bib183","doi-asserted-by":"crossref","first-page":"14689","DOI":"10.1200\/jco.2008.26.15_suppl.14689","article-title":"Preclinical evaluation of sunitinib, alone and in combination with trastuzumab, in HER2 positive breast cancer (BC)","volume":"26","author":"Tryfonopoulos","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib184","doi-asserted-by":"crossref","DOI":"10.1186\/bcr2903","article-title":"Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3","volume":"13","author":"Kodera","year":"2011","journal-title":"Breast Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib185","first-page":"1011","article-title":"Preclinical evaluation of the tyrosine kinase inhibitor SU11248 as a single agent and in combination with \u201cstandard of care\u201d therapeutic agents for the treatment of breast cancer","volume":"2","author":"Abrams","year":"2003","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.phrs.2026.108372_bib186","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8818393","article-title":"Sunitinib Combined with Th1 Cytokines Potentiates Apoptosis in Human Breast Cancer Cells and Suppresses Tumor Growth in a Murine Model of HER-2(pos) Breast Cancer","volume":"2021","author":"Ghimirey","year":"2021","journal-title":"Int. J. Breast Cancer"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib187","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1158\/0008-5472.CAN-16-1982","article-title":"Sunitinib Treatment Enhances Metastasis of Innately Drug-Resistant Breast Tumors","volume":"77","author":"Wragg","year":"2017","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib188","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.ccr.2009.01.021","article-title":"Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis","volume":"15","author":"Ebos","year":"2009","journal-title":"Cancer Cell."},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib189","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13058-020-01346-y","article-title":"Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence","volume":"22","author":"Wang","year":"2020","journal-title":"Breast Cancer Res."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib190","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1080\/15384047.2017.1294288","article-title":"Anti-angiogenic treatment promotes triple-negative breast cancer invasion via vasculogenic mimicry","volume":"18","author":"Sun","year":"2017","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib191","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1007\/s00262-022-03146-z","article-title":"The multitargeted receptor tyrosine kinase inhibitor sunitinib induces resistance of HER2 positive breast cancer cells to trastuzumab-mediated ADCC","volume":"71","author":"Guti","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"issue":"6","key":"10.1016\/j.phrs.2026.108372_bib192","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/j.breast.2012.09.002","article-title":"An exploratory study of sunitinib in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive metastatic breast cancer","volume":"21","author":"Cardoso","year":"2012","journal-title":"Breast"},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib193","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J. Clin. Oncol."},{"issue":"39","key":"10.1016\/j.phrs.2026.108372_bib194","doi-asserted-by":"crossref","first-page":"64089","DOI":"10.18632\/oncotarget.11596","article-title":"Phase Ib\/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer","volume":"7","author":"Wong","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib195","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.clbc.2021.05.009","article-title":"A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer","volume":"22","author":"Symonds","year":"2022","journal-title":"Clin. Breast Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib196","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s10549-010-0788-0","article-title":"Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer","volume":"121","author":"Barrios","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"9","key":"10.1016\/j.phrs.2026.108372_bib197","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1200\/JCO.2011.35.7376","article-title":"First-line treatment of advanced breast cancer with sunitinib in combination with docetaxel versus docetaxel alone: results of a prospective, randomized phase III study","volume":"30","author":"Bergh","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.phrs.2026.108372_bib198","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1200\/JCO.2012.43.3391","article-title":"Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer","volume":"31","author":"Crown","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"36","key":"10.1016\/j.phrs.2026.108372_bib199","doi-asserted-by":"crossref","first-page":"57894","DOI":"10.18632\/oncotarget.11082","article-title":"Sunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancer","volume":"7","author":"Sun","year":"2016","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.phrs.2026.108372_bib200","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib201","doi-asserted-by":"crossref","first-page":"3129","DOI":"10.1158\/1535-7163.MCT-08-0013","article-title":"Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling","volume":"7","author":"Wilhelm","year":"2008","journal-title":"Mol. Cancer Ther."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib202","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.12-4-426","article-title":"Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors","volume":"12","author":"Strumberg","year":"2007","journal-title":"oncologist"},{"issue":"24","key":"10.1016\/j.phrs.2026.108372_bib203","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","article-title":"Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5","volume":"66","author":"Liu","year":"2006","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib204","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"New. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib205","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"New. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.phrs.2026.108372_bib206","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1634\/theoncologist.2007-0233","article-title":"Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors","volume":"13","author":"Dal Lago","year":"2008","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib207","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00280-007-0639-9","article-title":"Safety and anti-tumor activity of sorafenib (Nexavar\u00ae) in combination with other anti-cancer agents: a review of clinical trials","volume":"61","author":"Takimoto","year":"2008","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"46","key":"10.1016\/j.phrs.2026.108372_bib208","doi-asserted-by":"crossref","first-page":"6861","DOI":"10.1038\/sj.onc.1208841","article-title":"The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006","volume":"24","author":"Yu","year":"2005","journal-title":"Oncogene"},{"issue":"25","key":"10.1016\/j.phrs.2026.108372_bib209","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.2174\/1381612023393026","article-title":"BAY 43-9006: preclinical data","volume":"8","author":"Wilhelm","year":"2002","journal-title":"Curr. Pharm. Des."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib210","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1159\/000505521","article-title":"Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells","volume":"98","author":"Dattachoudhury","year":"2020","journal-title":"Oncology"},{"key":"10.1016\/j.phrs.2026.108372_bib211","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.canlet.2018.03.037","article-title":"Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells","volume":"425","author":"Zanotto-Filho","year":"2018","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib212","doi-asserted-by":"crossref","first-page":"917","DOI":"10.3892\/or.2013.2228","article-title":"The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1alpha expression","volume":"29","author":"Lee","year":"2013","journal-title":"Oncol. Rep."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib213","doi-asserted-by":"crossref","first-page":"3185","DOI":"10.7314\/APJCP.2014.15.7.3185","article-title":"Investigation of antitumor effects of sorafenib and lapatinib alone and in combination on MCF-7 breast cancer cells","volume":"15","author":"Kacan","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.phrs.2026.108372_bib214","article-title":"Sorafenib (BAY 43-9006) inhibits the Raf\/MEK\/ERK pathway in hepatocellular carcinoma (HCC) cells and produces robust efficacy against PLC\/PRF\/5 HCC tumors in mice","author":"Liu","year":"2005","journal-title":"Poster Present. Am. Assoc. Cancer Res. Natl. Cancer Inst. Eur. Organ. Res. Treat. Cancer"},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib215","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1158\/1078-0432.CCR-05-2378","article-title":"BRAF is a therapeutic target in aggressive thyroid carcinoma","volume":"12","author":"Salvatore","year":"2006","journal-title":"Clin. Cancer Res."},{"issue":"15","key":"10.1016\/j.phrs.2026.108372_bib216","doi-asserted-by":"crossref","first-page":"5472","DOI":"10.1158\/1078-0432.CCR-04-2658","article-title":"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors","volume":"11","author":"Clark","year":"2005","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib217","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ejca.2010.08.019","article-title":"Sorafenib tosylate and paclitaxel induce anti-angiogenic, anti-tumour and anti-resorptive effects in experimental breast cancer bone metastases","volume":"47","author":"Merz","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib218","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s10549-009-0714-5","article-title":"Synergistic activity of letrozole and sorafenib on breast cancer cells","volume":"124","author":"Bonelli","year":"2010","journal-title":"Breast Cancer Res. Treat."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib219","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/CAD.0b013e32832b2ea0","article-title":"Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer","volume":"20","author":"Bianchi","year":"2009","journal-title":"Anti-Cancer Drugs"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib220","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1200\/JCO.2007.15.5242","article-title":"Phase II trial of sorafenib in patients with metastatic breast cancer previously exposed to anthracyclines or taxanes: North Central Cancer Treatment Group and Mayo Clinic Trial N0336","volume":"27","author":"Moreno-Aspitia","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.phrs.2026.108372_bib221","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1158\/1078-0432.CCR-12-3177","article-title":"Sorafenib or placebo with either gemcitabine or capecitabine in patients with HER-2\u2013negative advanced breast cancer that progressed during or after bevacizumab","volume":"19","author":"Schwartzberg","year":"2013","journal-title":"Clin. Cancer Res."},{"issue":"13","key":"10.1016\/j.phrs.2026.108372_bib222","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1200\/JCO.2011.36.7771","article-title":"Sorafenib in combination with capecitabine: an oral regimen for patients with HER2-negative locally advanced or metastatic breast cancer","volume":"30","author":"Baselga","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib223","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.ejca.2012.08.005","article-title":"A double-blind, randomised, placebo-controlled, phase 2b study evaluating sorafenib in combination with paclitaxel as a first-line therapy in patients with HER2-negative advanced breast cancer","volume":"49","author":"Gradishar","year":"2013","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib224","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/S0959-8049(11)70116-2","article-title":"A Double-blind, Randomized Phase lib Study Evaluating the Efficacy and Safety of Sorafenib (SOR) Compared to Placebo (PL) When Administered in Combination with Docetaxel And\/or Letrozole in Patients with Metastatic Breast Cancer (MBC): FM-B07-01 Trial","volume":"47","author":"Mariani","year":"2011","journal-title":"Eur. J. Cancer"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib225","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s10549-010-1226-z","article-title":"Phase I\/II study of sorafenib with anastrozole in patients with hormone receptor positive aromatase inhibitor resistant metastatic breast cancer","volume":"125","author":"Isaacs","year":"2011","journal-title":"Breast Cancer Res. Treat."},{"issue":"15","key":"10.1016\/j.phrs.2026.108372_bib226","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.2217\/fon.14.99","article-title":"Impact of adding the multikinase inhibitor sorafenib to endocrine therapy in metastatic estrogen receptor-positive breast cancer","volume":"10","author":"Massarweh","year":"2014","journal-title":"Future Oncol."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib227","first-page":"280","article-title":"A pilot study of adjuvant doxorubicin and cyclophosphamide followed by paclitaxel and sorafenib in women with node-positive or high-risk early-stage breast cancer","volume":"9","author":"Spigel","year":"2011","journal-title":"Clin. Adv. Hematol. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib228","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1159\/000363430","article-title":"Sorafenib in the Treatment of Early Breast Cancer: Results of the Neoadjuvant Phase II Study - SOFIA","volume":"9","author":"Loibl","year":"2014","journal-title":"Breast Care (Basel)"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib229","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1038\/bjc.2014.563","article-title":"Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer","volume":"112","author":"Bazzola","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.phrs.2026.108372_bib230","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.clbc.2017.05.006","article-title":"RESILIENCE: phase III randomized, double-blind trial comparing sorafenib with capecitabine versus placebo with capecitabine in locally advanced or metastatic HER2-negative breast cancer","volume":"17","author":"Baselga","year":"2017","journal-title":"Clin. Breast Cancer"},{"key":"10.1016\/j.phrs.2026.108372_bib231","series-title":"Seminars in oncology","article-title":"Nilotinib: a novel, selective tyrosine kinase inhibitor","author":"Blay","year":"2011"},{"issue":"1-2","key":"10.1016\/j.phrs.2026.108372_bib232","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.bbapap.2005.07.040","article-title":"Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia","volume":"1754","author":"Manley","year":"2005","journal-title":"Biochim. Biophys. Acta"},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib233","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell."},{"key":"10.1016\/j.phrs.2026.108372_bib234","doi-asserted-by":"crossref","DOI":"10.3389\/fmolb.2023.1215204","article-title":"Machine learning-driven exploration of drug therapies for triple-negative breast cancer treatment","volume":"10","author":"Kaushik","year":"2023","journal-title":"Front. Mol. Biosci."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib235","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0118854","article-title":"ABL tyrosine kinase inhibition variable effects on the invasive properties of different triple negative breast cancer cell lines","volume":"10","author":"Chevalier","year":"2015","journal-title":"PLoS. One"},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib236","doi-asserted-by":"crossref","first-page":"975","DOI":"10.4149\/neo_2021_201126N1282","article-title":"Nilotinib, a Discoidin domain receptor 1 (DDR1) inhibitor, induces apoptosis and inhibits migration in breast cancer","volume":"68","author":"Wang","year":"2021","journal-title":"Neoplasma"},{"issue":"15","key":"10.1016\/j.phrs.2026.108372_bib237","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158702","article-title":"c-Kit Induces Migration of Triple-Negative Breast Cancer Cells and Is a Promising Target for Tyrosine Kinase Inhibitor Treatment","volume":"23","author":"Lopez-Mejia","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.phrs.2026.108372_bib238","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0095663","article-title":"Geminin overexpression promotes imatinib sensitive breast cancer: a novel treatment approach for aggressive breast cancers, including a subset of triple negative","volume":"9","author":"Blanchard","year":"2014","journal-title":"PLoS. One"},{"issue":"31","key":"10.1016\/j.phrs.2026.108372_bib239","doi-asserted-by":"crossref","first-page":"22158","DOI":"10.18632\/oncotarget.25243","article-title":"Targeting invadopodia-mediated breast cancer metastasis by using ABL kinase inhibitors","volume":"9","author":"Meirson","year":"2018","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib240","doi-asserted-by":"crossref","DOI":"10.1186\/bcr3191","article-title":"Preclinical and clinical studies of estrogen deprivation support the PDGF\/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer","volume":"14","author":"Weigel","year":"2012","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib241","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.3892\/ijo.2014.2619","article-title":"Sorafenib and nilotinib resensitize tamoxifen resistant breast cancer cells to tamoxifen treatment via estrogen receptor alpha","volume":"45","author":"Pedersen","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.phrs.2026.108372_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.115185","article-title":"Enhanced in vivo targeting of estrogen receptor alpha signaling in murine mammary adenocarcinoma by nilotinib\/rosuvastatin novel combination","volume":"404","author":"Goda","year":"2020","journal-title":"Toxicol. Appl. Pharmacol."},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib243","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.neo.2017.08.009","article-title":"Nilotinib Enhances Tumor Angiogenesis and Counteracts VEGFR2 Blockade in an Orthotopic Breast Cancer Xenograft Model with Desmoplastic Response","volume":"19","author":"Zafarnia","year":"2017","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib244","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1186\/s13104-025-07206-2","article-title":"Results of the preclinical multicenter randomized controlled paclitaxel-induced neuropathy prevention replication study (PINPRICS)","volume":"18","author":"Boehmerle","year":"2025","journal-title":"BMC Res. Notes"},{"issue":"8","key":"10.1016\/j.phrs.2026.108372_bib245","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1078-0432.CCR-22-3334","article-title":"National Cancer Institute Combination Therapy Platform Trial with Molecular Analysis for Therapy Choice (ComboMATCH)","volume":"29","author":"Meric-Bernstam","year":"2023","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib246","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1002\/ajh.27443","article-title":"Chronic myeloid leukemia: 2025 update on diagnosis, therapy, and monitoring","volume":"99","author":"Jabbour","year":"2024","journal-title":"Am. J. Hematol."},{"issue":"18","key":"10.1016\/j.phrs.2026.108372_bib247","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1182\/blood-2014-09-601674","article-title":"Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina","volume":"125","author":"Wang","year":"2015","journal-title":"Blood"},{"issue":"24","key":"10.1016\/j.phrs.2026.108372_bib248","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia","volume":"362","author":"Saglio","year":"2010","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.phrs.2026.108372_bib249","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1158\/1078-0432.CCR-09-0542","article-title":"A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors","volume":"15","author":"Demetri","year":"2009","journal-title":"Clin. Cancer Res."},{"issue":"20","key":"10.1016\/j.phrs.2026.108372_bib250","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1002\/cncr.26120","article-title":"Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor","volume":"117","author":"Sawaki","year":"2011","journal-title":"Cancer"},{"issue":"13","key":"10.1016\/j.phrs.2026.108372_bib251","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.ejca.2009.04.030","article-title":"Nilotinib in the treatment of advanced gastrointestinal stromal tumours resistant to both imatinib and sunitinib","volume":"45","author":"Montemurro","year":"2009","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib252","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1093\/annonc\/mdr598","article-title":"Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib","volume":"23","author":"Reichardt","year":"2012","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.phrs.2026.108372_bib253","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s10637-011-9763-9","article-title":"Nilotinib in patients with metastatic melanoma harboring KIT gene aberration","volume":"30","author":"Cho","year":"2012","journal-title":"Invest. New. Drugs"},{"issue":"21","key":"10.1016\/j.phrs.2026.108372_bib254","doi-asserted-by":"crossref","first-page":"5239","DOI":"10.1158\/1078-0432.CCR-18-0851","article-title":"Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma","volume":"24","author":"Alemany","year":"2018","journal-title":"Clin. Cancer Res."},{"issue":"11","key":"10.1016\/j.phrs.2026.108372_bib255","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1158\/1078-0432.CCR-24-3049","article-title":"A Phase I Study of Nilotinib in Combination with Paclitaxel in Patients with Advanced Solid Tumors","volume":"31","author":"Shin","year":"2025","journal-title":"Clin. Cancer Res."},{"issue":"31","key":"10.1016\/j.phrs.2026.108372_bib256","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1200\/JCO.2009.21.8487","article-title":"Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers","volume":"27","author":"Lewis","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.phrs.2026.108372_bib257","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"1","key":"10.1016\/j.phrs.2026.108372_bib258","article-title":"Phase I study using crenolanib to target PDGFR kinase in children and young adults with newly diagnosed DIPG or recurrent high-grade glioma, including DIPG","volume":"3","author":"Tinkle","year":"2021","journal-title":"Neurooncol. Adv."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib259","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s00280-021-04384-1","article-title":"Phase I\/Ib study of crenolanib with ramucirumab and paclitaxel as second-line therapy for advanced esophagogastric adenocarcinoma","volume":"89","author":"Moy","year":"2022","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"16","key":"10.1016\/j.phrs.2026.108372_bib260","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1158\/1078-0432.CCR-12-0625","article-title":"Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors","volume":"18","author":"Heinrich","year":"2012","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.phrs.2026.108372_bib261","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1053\/j.gastro.2015.04.006","article-title":"Platelet-Derived Growth Factor Receptor-alpha Regulates Proliferation of Gastrointestinal Stromal Tumor Cells With Mutations in KIT by Stabilizing ETV1","volume":"149","author":"Hayashi","year":"2015","journal-title":"Gastroenterology"},{"issue":"22","key":"10.1016\/j.phrs.2026.108372_bib262","doi-asserted-by":"crossref","first-page":"3607","DOI":"10.1182\/blood-2013-07-513044","article-title":"Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia","volume":"122","author":"Zimmerman","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2026.108372_bib263","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.2147\/OTT.S68773","article-title":"Crenolanib, a PDGFR inhibitor, suppresses lung cancer cell proliferation and inhibits tumor growth in vivo","volume":"7","author":"Wang","year":"2014","journal-title":"Onco Targets Ther."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib264","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.3390\/cimb43030122","article-title":"Crosstalk between Cancer Cells and Fibroblasts for the Production of Monocyte Chemoattractant Protein-1 in the Murine 4T1 Breast Cancer","volume":"43","author":"Imamura","year":"2021","journal-title":"Curr. Issues Mol. Biol."},{"issue":"15","key":"10.1016\/j.phrs.2026.108372_bib265","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1200\/JCO.23.01061","article-title":"Crenolanib and Intensive Chemotherapy in Adults With Newly Diagnosed FLT3-Mutated AML","volume":"42","author":"Wang","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.phrs.2026.108372_bib266","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/0008-5472.957.65.3","article-title":"Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451","volume":"65","author":"Roberts","year":"2005","journal-title":"Cancer Res."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib267","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1158\/0008-5472.CAN-12-1646","article-title":"Distinct effects of ligand-induced PDGFR\u03b1 and PDGFR\u03b2 signaling in the human rhabdomyosarcoma tumor cell and stroma cell compartments","volume":"73","author":"Ehnman","year":"2013","journal-title":"Cancer Res."},{"key":"10.1016\/j.phrs.2026.108372_bib268","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.2147\/OTT.S62946","article-title":"CP-673451, a platelet-derived growth-factor receptor inhibitor, suppresses lung cancer cell proliferation and migration","volume":"7","author":"Xi","year":"2014","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.phrs.2026.108372_bib269","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.toxlet.2018.05.033","article-title":"Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism","volume":"295","author":"Yang","year":"2018","journal-title":"Toxicol. Lett."},{"issue":"7","key":"10.1016\/j.phrs.2026.108372_bib270","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1038\/s41418-019-0485-4","article-title":"Synergistic therapeutic effect of combined PDGFR and SGK1 inhibition in metastasis-initiating cells of breast cancer","volume":"27","author":"Yang","year":"2020","journal-title":"Cell. Death Differ."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002872?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661826002872?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:00:27Z","timestamp":1789398027000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661826002872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":270,"alternative-id":["S1043661826002872"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108372","relation":{},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical utilities of platelet-derived growth factor signaling in breast cancer","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2026.108372","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"108372"}}